<h1>Foreign investment approvals in pharmaceuticals permit increased FII and QIB equity stakes, subject to manufacturing and R&D conditions.</h1> Approvals allow Qualified Institutional Buyers to infuse fresh equity into Aurobindo (up to seven percent additional QIB equity) and raise FII limits in Glenmark to forty-nine percent, facilitating foreign capital inflows to support manufacturing and therapeutic-area expansion. Both companies must continue production of medicines on the National List of Essential Medicines at prior levels, maintain R&D expenditure at the maximum levels of the past three years, and provide complete information on technology transfer.